Terumo Corporation (OTCPK:TRUMF) Q1 202 Earnings Conference Call August 9, 2022 4:00 AM ET
Naoki Muto - Chief Accounting and Financial Officer
I am the CAFO, Muto. I will now explain the First Quarter Results for the Fiscal Year-Ending March 2023. First, the highlights of this earn
The latest published report provides global insights into the Condom Catheters Market 2022. The report summarizes the result of the assessment in the field of Condom Catheters Market from a global perspective. The report provides Condom Catheters market size analysis By Types, Applicatio
July 21, 2022 10:51 ET | Source: ReportLinker ReportLinker
New York, July 21, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the rel
Javascript is currently disabled in your browser. Several features of this site will not function whilst javascript is disabled.
open access to scientific and medical research
From submission to first editorial decision.
From editorial acceptance to publication.
The a
Scope of Urinary Catheter industry 2022-2032 | insightSLICE
Permanent link to this press release:
Delete press release
Updates best practice advice to support non-endoscopic esophageal precancer screening and significantly expands target population to include, for the first time, at-risk patients without chronic heartburn symptoms
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commerc
Agreements with three PPOs and a specialized laboratory network expand Lucid’s reach, providing in-network access and payment for its EsoGuard® DNA test to millions of additional covered lives
NEW YORK--(BUSINESS WIRE )--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Co
Agreements with three PPOs and a specialized laboratory network expand Lucid’s reach, providing in-network access and payment for its EsoGuard® DNA test to millions of additional covered lives
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “
"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."
Cureus is on a mission to change the long-standing paradigm of medical publishing, where submitting research can be costly, complex and time-consuming.
Updates best practice advice to support non-endoscopic esophageal precancer screening and significantly expands target population to include, for the first time, at-risk patients without chronic heartburn symptoms
NEW YORK--(BUSINESS WIRE )--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“